Sight Sciences, Inc. (SGHT) Presents at Morgan Stanley 23rd Annual Global Healthcare

Industry Overview - Glaucoma is the leading cause of irreversible blindness globally, highlighting the critical need for effective treatment options [1] - The market for Minimally Invasive Glaucoma Surgery (MIGS) is expected to return to growth by 2026, despite current challenges [2] Market Dynamics - There has been significant progress in MIGS, improving clinical outcomes for patients with glaucoma [1] - The industry is currently facing headwinds due to changes in Local Coverage Determinations (LCDs), but these challenges are anticipated to ease by Q4 [1]